Publication

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial

Journal Paper/Review - Feb 14, 2019

Neurooncology Working Group of the German Cancer Society, Simon Matthias, Tonn Jörg-Christian, Stummer Walter, Schaub Christina, Weller Johannes, Kebir Sied, Schäfer Niklas, Stuplich Moritz, Vatter Hartmut, Misch Martin, Keil Vera C, Nelles Michael, Glas Martin, Coch Christoph, Pietsch Torsten, Hattingen Elke, Schmid Matthias, Fimmers Rolf, Weller Michael, Wick Wolfgang, Coenen Martin, Urbach Horst, Vajkoczy Peter, Galldiks Norbert, Bullinger Lars, Goldbrunner Roland, Grauer Oliver, Krex Dietmar, Kortmann Rolf-Dieter, Hau Peter, Sabel Michael, Schlegel Uwe, Steinbach Joachim Peter, Mack Frederic, Tzaridis Theophilos, Schnell Oliver, Bähr Oliver, Renovanz Miriam, Weyerbrock Astrid, Brehmer Stefanie, Suchorska Bogdana, Schmidt-Graf Friederike, Ringel Florian, Kowalski Thomas, Tabatabai Ghazaleh, Seidel Clemens, Uhl Martin, Herrlinger Ulrich